EA032840B8 - Пролекарства на основе конъюгатов противогрибковых агентов и их применение - Google Patents

Пролекарства на основе конъюгатов противогрибковых агентов и их применение

Info

Publication number
EA032840B8
EA032840B8 EA201490100A EA201490100A EA032840B8 EA 032840 B8 EA032840 B8 EA 032840B8 EA 201490100 A EA201490100 A EA 201490100A EA 201490100 A EA201490100 A EA 201490100A EA 032840 B8 EA032840 B8 EA 032840B8
Authority
EA
Eurasian Patent Office
Prior art keywords
ranges
prodrugs
afa
conjugate
based antifungal
Prior art date
Application number
EA201490100A
Other languages
English (en)
Other versions
EA201490100A1 (ru
EA032840B1 (ru
Inventor
Абхижит С. Бапат
Гаутхами Манеш
Ражеш С. Гокхале
Сайали С. Шах
Шиладитиа Сенгупта
Судхананд Прасад
Сумана Гхош
Суреш Р. Чавраи
Нидхи Арора
Д. Сридхар Редди
Маллика Мишра
Кирти Бажаж
Original Assignee
Вайоми Терапеутикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайоми Терапеутикс Лимитед filed Critical Вайоми Терапеутикс Лимитед
Publication of EA201490100A1 publication Critical patent/EA201490100A1/ru
Publication of EA032840B1 publication Critical patent/EA032840B1/ru
Publication of EA032840B8 publication Critical patent/EA032840B8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8129—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

В настоящем изобретении предложены пролекарства на основе конъюгатов противогрибковых агентов, получаемые путем связывания по меньшей мере одного противогрибкового агента по меньшей мере с одним линкером и носителем, а также их применение для лечения или предотвращения грибковых инфекций. Пролекарства имеют формулу (i) (AFA)-X-(L); (ii) [(AFA)-X]-L или (iii) AFA-[X-(L)], где AFA представляет собой противогрибковый агент; L представляет собой носитель; X представляет собой линкер; m составляет от 1 до 10; n составляет от 2 до 10; m' составляет от 1 до 10; р составляет от 1 до 10; n' составляет от 1 до 10; q составляет от 1 до 10 при условии, что оба q и n' одновременно не равняются 1.
EA201490100A 2011-06-22 2012-06-22 Пролекарства на основе конъюгатов противогрибковых агентов и их применение EA032840B8 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1770DE2011 2011-06-22
US201161514305P 2011-08-02 2011-08-02
PCT/US2012/043717 WO2012177986A2 (en) 2011-06-22 2012-06-22 Conjugate-based antifungal and antibacterial prodrugs

Publications (3)

Publication Number Publication Date
EA201490100A1 EA201490100A1 (ru) 2014-11-28
EA032840B1 EA032840B1 (ru) 2019-07-31
EA032840B8 true EA032840B8 (ru) 2020-06-18

Family

ID=47423228

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490100A EA032840B8 (ru) 2011-06-22 2012-06-22 Пролекарства на основе конъюгатов противогрибковых агентов и их применение

Country Status (11)

Country Link
US (2) US9907812B2 (ru)
EP (1) EP2723452A2 (ru)
JP (2) JP6336902B2 (ru)
KR (1) KR20140057414A (ru)
CN (1) CN103857440B (ru)
AU (1) AU2012272804B2 (ru)
BR (1) BR112013033239A2 (ru)
CA (1) CA2840215A1 (ru)
EA (1) EA032840B8 (ru)
MX (1) MX2013015434A (ru)
WO (1) WO2012177986A2 (ru)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2509159B (en) * 2012-12-21 2017-07-26 Oxoid Ltd Triclosan derivatives and uses thereof
WO2014167554A2 (en) * 2013-04-12 2014-10-16 Vyome Biosciences Pvt. Ltd. Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
US20140377356A1 (en) * 2013-06-19 2014-12-25 Professional Compounding Centers Of America (Pcca) Inhalation Composition for Treating Respiratory Tract Infections
WO2014206866A1 (en) * 2013-06-24 2014-12-31 F. Hoffmann-La Roche Ag Stable intravenous formulation
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104422750B (zh) * 2013-09-05 2016-02-10 中国科学院大连化学物理研究所 一种烟叶中磷脂酰乙醇胺与甘油三酯含量的检测方法
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment
DK2838510T3 (en) 2013-11-08 2016-12-19 Lilly Co Eli Atomoxetine solution
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR101620148B1 (ko) * 2013-12-19 2016-05-12 주식회사 바이오에프디엔씨 항균펩타이드 베타-디펜신 ３ 및 ３ｈ의 라우릭산 융합을 통한 장기지속형 유도체, 세포투과성 펩타이드 융합을 통한 피부투과형 유도체 개발과 이를 함유하는 화장료 조성물
BR112016017690A2 (pt) * 2014-01-29 2017-08-08 Vyome Biosciences Pvt Ltd Tratamentos para acne resistente
WO2015164289A1 (en) * 2014-04-21 2015-10-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11478497B2 (en) * 2014-12-18 2022-10-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating eukaryotic infections via altering aggregation dynamics of Raptor/KOG1
CN104627958B (zh) * 2015-01-30 2016-03-16 四川大学 一种稳定性增强的改性纳米粒子及其制备方法
CN104971357B (zh) * 2015-03-20 2018-04-17 南京星银药业集团有限公司 Peg修饰的棘白菌素类抗真菌药物复合物及其制备
MX2018003258A (es) * 2015-09-20 2019-02-07 Air Cross Inc Ozonolisis para la activacion de compuestos y degradacion de ozono.
EP3353159A4 (en) 2015-09-22 2019-03-27 The Regents of The University of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
CN105521020B (zh) * 2015-11-17 2021-06-18 安徽师范大学 具有控制人体皮肤病活性的植物提取物组合物
CN108367050A (zh) 2015-12-14 2018-08-03 荷兰联合利华有限公司 抗微生物组合物
CN106913520A (zh) * 2015-12-25 2017-07-04 上海医药集团股份有限公司 艾沙康唑的微粒给药组合物
CN106551803A (zh) * 2016-04-11 2017-04-05 张梦兮 吡罗克酮类化合物在制备预防口腔黏膜疾病的保健制品上的用途
WO2018031782A1 (en) * 2016-08-10 2018-02-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Nanoparticle compositions and methods for enhanced stability and delivery of glycopeptide drugs
WO2018033470A1 (en) 2016-08-19 2018-02-22 Unilever N.V. An antimicrobial composition
US10617621B2 (en) 2016-08-19 2020-04-14 Conopco, Inc. Antimicrobial composition
CN106307543B (zh) * 2016-08-22 2020-02-07 青岛农业大学 一种麝香草酚纳米脂质体及其制备方法
CN106366285A (zh) * 2016-09-09 2017-02-01 福州维亚生物科技有限公司 一种血管支架的制备和使用方法
RU2766086C2 (ru) 2016-10-14 2022-02-07 Пулматрикс Оперэйтинг Компани, Инк. Противогрибковые сухие порошки
GB2555391B (en) * 2016-10-21 2019-06-26 Algipharma As Bacitracin-alginate oligomer conjugates
CN106432478B (zh) * 2016-10-25 2019-10-11 齐鲁工业大学 一种胶原蛋白的抗菌改性方法
BR112019008463B1 (pt) 2016-10-28 2022-06-07 Unilever Ip Holdings B.V. Composição para a higiene pessoal
US11253458B2 (en) 2016-10-28 2022-02-22 Conopco, Inc. Personal care composition comprising particles
CN106727670B (zh) * 2016-11-17 2019-06-14 温州医科大学 一种抗细菌兼抗真菌作用的胶束制剂及制备方法
SG10202105118WA (en) 2016-11-28 2021-06-29 Cellix Bio Private Ltd Compositions and methods for the treatment of fungal infections
CN106674224A (zh) * 2016-12-20 2017-05-17 天津迈德新医药科技有限公司 mPEG4‑阿巴卡韦及其制备方法和应用
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
US20200138964A1 (en) * 2017-04-25 2020-05-07 Seikagaku Corporation Tertiary amine compound or imine compound-polymer conjugate and production method therefor
CR20190524A (es) * 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CR20200033A (es) 2017-06-26 2020-03-05 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
SE541313C2 (en) * 2017-10-13 2019-06-25 Amferia Ab Amphiphilic antimicrobial hydrogel
US11564963B2 (en) 2017-11-22 2023-01-31 Progeneron, Llc Topical compositions, process of large-scale manufacture, and method of use
WO2019104249A1 (en) * 2017-11-22 2019-05-31 Progeneron Topical compositions, process of manufacture and method of use
WO2019109065A1 (en) * 2017-12-01 2019-06-06 The Children's Medical Center Corporation Covalent anesthetic-polymer conjugates for prolonged local anesthesia
JP7345478B2 (ja) * 2018-01-17 2023-09-15 ザ・セカント・グループ・エルエルシー ｐＨを調節する生分解性ポリマーおよびポリ（グリセロールセバシン酸）で増強された細胞培養培地
WO2019191597A1 (en) * 2018-03-30 2019-10-03 The Board Of Regents Of The University Of Oklahoma Very long chain saturated fatty acid compounds, compositions containing same, and methods of use
CN113166189A (zh) * 2018-04-26 2021-07-23 纳米医学控股有限公司 吉西他滨两亲性前体药物
CN108524945B (zh) * 2018-05-21 2019-12-17 广东海洋大学 一种庆大霉素改性壳聚糖的制备方法
CN108743603B (zh) * 2018-06-22 2020-06-30 山东省千佛山医院 利巴韦林单用或联合氟康唑的抗真菌产品及其应用
WO2020050378A1 (ja) * 2018-09-06 2020-03-12 生化学工業株式会社 第３級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
CN109528639A (zh) * 2018-12-24 2019-03-29 江西润泽药业有限公司 一种用于制备复方盐酸林可霉素注射液的方法
JP7378929B2 (ja) 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
CN109679328B (zh) * 2018-12-28 2021-08-24 山东一诺威体育产业有限公司 快速固化低温柔韧性聚氨酯粘合剂及其制备方法和使用方法
EP3962533A4 (en) 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
WO2020242857A1 (en) * 2019-05-24 2020-12-03 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
BR112021025848A2 (pt) * 2019-08-01 2022-02-08 Unilever Ip Holdings B V Composição antimicrobiana, método para inibir o crescimento de m. furfur e uso de uma composição
US20220280401A1 (en) * 2019-08-01 2022-09-08 Conopco, Inc., D/B/A Unilever An antidandruff composition
US20220313717A1 (en) * 2019-08-13 2022-10-06 Matinas Biopharma Nanotechnologies, Inc. Methods of treating cryptococcus infections
KR102331879B1 (ko) * 2019-09-20 2021-11-29 의료법인 성광의료재단 특수 코팅된 나노입자 및 그의 이용
CN110898230B (zh) * 2019-12-27 2022-11-22 中国医学科学院放射医学研究所 一种基于三氯生的纳米抗生素水凝胶及其制备方法与应用
CN111440124B (zh) * 2020-04-27 2023-01-17 中国海洋大学 一种5-氟尿嘧啶与咖啡酸的共晶及其制备方法
WO2021226166A1 (en) * 2020-05-07 2021-11-11 Liang Guibai Prodrug of itraconazole and use thereof
US20240092878A1 (en) * 2020-05-17 2024-03-21 Abgenics Lifesciences Private Limited An antibody fragment based antifungal conjugate selectively targeting candida
CN111821512B (zh) * 2020-06-19 2022-06-14 上海大学 酶响应释药聚l-谷氨酸/壳聚糖多孔复合微载体、其制备方法及其应用
CN111840264B (zh) * 2020-08-14 2023-04-07 华中科技大学协和深圳医院 西塞卡那用于抑制革兰阳性细菌生物活性的用途
EP4209229A4 (en) * 2020-09-04 2024-07-31 Univ Osaka LIPOSOME PREPARATION WITH ANTIBACTERIAL ACTIVE INGREDIENT
KR20220035334A (ko) * 2020-09-09 2022-03-22 난징 헤론 파마슈티컬 사이언스 앤 테크놀로지 컴퍼니 리미티드 아릴프로피온산 유도체, 약학적 조성물 및 이의 제조방법과 응용
RU2764574C1 (ru) * 2020-10-16 2022-01-18 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук Средство для лечения акне
WO2022084929A1 (en) * 2020-10-23 2022-04-28 Universita' Degli Studi Di Modena E Reggio Emilia Nanoparticles for transport across the blood-brain barrier
US12090133B2 (en) * 2020-11-05 2024-09-17 The Mentholatum Company Topical composition
CN112625071B (zh) * 2020-12-30 2022-07-29 海南海神同洲制药有限公司 一种盐酸克林霉素棕榈酸酯的合成工艺
CN112914174B (zh) * 2021-01-26 2023-06-30 成都中医药大学 一种抗菌除臭口罩及其制备方法
CN113082000B (zh) * 2021-04-30 2022-11-15 哈尔滨职业技术学院 Bs固体脂质纳米递药系统的制备方法及应用
CA3230380A1 (en) 2021-09-01 2023-03-09 Nicholas MORRA Synthesis of mdma or its optically active (r)- or (s)-mdma isomers
EP4408832A1 (en) 2021-10-01 2024-08-07 Empathibio, Inc. Novel prodrugs of mdma, mda, and derivatives thereof
BR102021019756A2 (pt) * 2021-10-01 2023-04-18 Chemyunion Ltda Composição antissebogênica, formulação e uso da composição
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CN114230619A (zh) * 2022-01-05 2022-03-25 浙江天台药业股份有限公司 一种盐酸克林霉素棕榈酸酯杂质的分离纯化方法
WO2023187197A1 (en) 2022-03-31 2023-10-05 Université De Genève Conjugates of antimicrobial agents with a tocopheryl or tocotrienyl group
CN116063746B (zh) * 2022-08-18 2024-04-02 中国农业科学院深圳农业基因组研究所 提升壳聚糖材料机械性能的方法及制备的壳聚糖复合材料
CN115137733B (zh) * 2022-08-24 2024-01-02 吉林大学 熊去氧胆酸在制备mcr-3酶抑制剂中的应用
WO2024058975A1 (en) * 2022-09-14 2024-03-21 Ultra, Llc Modified cholic acid conjugates
WO2024148293A1 (en) * 2023-01-05 2024-07-11 William Marsh Rice University Charged pi-conjugated molecules for the treatment of microbial infections
CN117959302B (zh) * 2024-03-29 2024-07-02 中国农业大学 5-氟尿嘧啶联合美罗培南在抑制美罗培南耐药菌中的应用
CN118164975B (zh) * 2024-05-14 2024-08-09 中国医学科学院医药生物技术研究所 一种季铵盐类噁唑烷酮衍生物及其可药用盐、制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
WO2007023398A2 (en) * 2005-05-16 2007-03-01 Universite De Geneve Compounds for photochemotherapy
US20070292404A1 (en) * 2006-03-27 2007-12-20 Biosynexus Incorporated Antimicrobial polymer conjugates
WO2008034019A2 (en) * 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
WO2008089185A2 (en) * 2007-01-16 2008-07-24 Enzon Pharmaceuticals, Inc. Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2826551A (en) 1954-01-04 1958-03-11 Simoniz Co Nontangling shampoo
GB849433A (en) 1957-08-22 1960-09-28 Raymond Woolston Hair washing preparations
US3784694A (en) * 1963-02-22 1974-01-08 Ciba Geigy Corp Halogenated 2-acyloxy-diphenylethers as bactericides and fungicides
US3958581A (en) 1972-05-17 1976-05-25 L'oreal Cosmetic composition containing a cationic polymer and divalent metal salt for strengthening the hair
CA1018893A (en) 1972-12-11 1977-10-11 Roger C. Birkofer Mild thickened shampoo compositions with conditioning properties
US3964500A (en) 1973-12-26 1976-06-22 Lever Brothers Company Lusterizing shampoo containing a polysiloxane and a hair-bodying agent
US4217914A (en) 1974-05-16 1980-08-19 L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4422853A (en) 1974-05-16 1983-12-27 L'oreal Hair dyeing compositions containing quaternized polymer
AT365448B (de) 1975-07-04 1982-01-11 Oreal Kosmetische zubereitung
US4197865A (en) 1975-07-04 1980-04-15 L'oreal Treating hair with quaternized polymers
US4313889A (en) * 1975-09-22 1982-02-02 Merck & Co., Inc. Soft quaternary surface active agents
US4204065A (en) * 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
US4177177A (en) 1976-03-26 1979-12-04 El Aasser Mohamed S Polymer emulsification process
US4152416A (en) 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4507280A (en) 1979-07-02 1985-03-26 Clairol Incorporated Hair conditioning composition and method for use
US4663158A (en) 1979-07-02 1987-05-05 Clairol Incorporated Hair conditioning composition containing cationic polymer and amphoteric surfactant and method for use
US4529586A (en) 1980-07-11 1985-07-16 Clairol Incorporated Hair conditioning composition and process
US4431809A (en) 1981-04-13 1984-02-14 Eli Lilly And Company Antibiotic A-33853 derivatives
US4364837A (en) 1981-09-08 1982-12-21 Lever Brothers Company Shampoo compositions comprising saccharides
US4942162A (en) 1982-03-31 1990-07-17 University Of Tennessee Research Corporation Topical treatment of seborrheic dermatitis with ketoconazole
GB8313634D0 (en) * 1982-06-18 1983-06-22 Ici Plc Halogenophenyl glyceride esters
US4588525A (en) 1984-02-27 1986-05-13 Molecular Biosystems, Inc. Prodrug compounds for dermal application
EP0178152B1 (en) * 1984-10-09 1991-09-25 Eli Lilly And Company Production of a-21978c derivatives
USRE34584E (en) 1984-11-09 1994-04-12 The Procter & Gamble Company Shampoo compositions
CA1261276A (en) 1984-11-09 1989-09-26 Mark B. Grote Shampoo compositions
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3531971A1 (de) 1985-09-07 1987-03-19 Henkel Kgaa Oel-in-wasser-emulsion
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
FR2598420B1 (fr) * 1986-05-06 1991-06-07 Oreal Nouveaux esters retinoiques d'antibiotiques, leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
DE3805882C1 (ru) 1988-02-25 1989-07-13 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh, 1000 Berlin, De
JPH02204413A (ja) * 1989-02-02 1990-08-14 Nonogawa Shoji:Kk 抗真菌外用製剤
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5106609A (en) 1990-05-01 1992-04-21 The Procter & Gamble Company Vehicle systems for use in cosmetic compositions
US5104646A (en) 1989-08-07 1992-04-14 The Procter & Gamble Company Vehicle systems for use in cosmetic compositions
JP3918119B2 (ja) 1993-01-21 2007-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 局所用ケトコナゾール組成物
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
DE4404018A1 (de) * 1994-02-09 1995-08-10 Merck Patent Gmbh Protrahiert freisetzende Darreichungsformen enthaltend Clindamycin-Palmitat
US5456851A (en) 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
TW460296B (en) 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
JPH11508231A (ja) 1995-05-26 1999-07-21 ソマティックス セラピー コーポレイション 安定な脂質／核酸複合体を含む送達ビヒクル
US6013250A (en) 1995-06-28 2000-01-11 L'oreal S. A. Composition for treating hair against chemical and photo damage
US5607980A (en) 1995-07-24 1997-03-04 The Procter & Gamble Company Topical compositions having improved skin feel
EP0866804B1 (de) 1995-12-16 2001-09-19 Planton GmbH, Gegen bakterien, mycota und viren wirksame vertebraten proteine und dessen kosmetische zubereitungen
US5750122A (en) 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
US5674478A (en) 1996-01-12 1997-10-07 The Procter & Gamble Company Hair conditioning compositions
TW446563B (en) 1996-01-16 2001-07-21 Colgate Palmolive Co Low static conditioning shampoo
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US5847003A (en) 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
CA2261887C (en) * 1996-07-23 2007-10-02 Oregon Health Sciences University Covalent polar lipid conjugates with biologically-active compounds for use in salves
NZ328607A (en) * 1996-09-09 1999-08-30 Hoffmann La Roche Heterocyclically substituted n-benzyl-azolium derivatives and fungicidal compositions
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
JP3545588B2 (ja) 1997-03-24 2004-07-21 株式会社資生堂 毛髪化粧料
JP3108997B2 (ja) * 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
AU2052599A (en) 1997-12-12 1999-07-05 Ciba Specialty Chemicals Holding Inc. O-derivatives of halogenated diphenyl ether compounds
US6099870A (en) 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
FR2774588B1 (fr) 1998-02-11 2000-05-05 Oreal Composition cosmetique ou dermatologique contenant au moins une proteine de soie d'arachnides naturelle, recombinante ou un analogue
US6265584B1 (en) 1998-05-22 2001-07-24 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP2000086655A (ja) * 1998-09-16 2000-03-28 Takeda Chem Ind Ltd トリアゾール化合物、その製造法および用途
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
KR20000051143A (ko) 1999-01-19 2000-08-16 김충섭 불소화 비닐기가 치환된 신규의 아졸계 유도체 및 그의 제조방법
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
US6649155B1 (en) 1999-05-03 2003-11-18 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing certain cationic polymers
US6451300B1 (en) 1999-05-03 2002-09-17 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers
US6974569B2 (en) 1999-05-03 2005-12-13 The Procter & Gamble Company Shampoos providing a superior combination anti-dandruff efficacy and condition
CA2309373A1 (en) 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US6524594B1 (en) 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
FR2795315B1 (fr) 1999-06-25 2001-08-10 Oreal Compositions cosmetiques contenant un polymere amphotere et un agent antipelliculaire et leurs utilisations
DE19938404A1 (de) 1999-08-13 2001-02-22 Clariant Gmbh Kosmetische Zubereitungen
KR100360827B1 (ko) 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6812238B1 (en) 1999-11-02 2004-11-02 Basilea Pharmaceutica Ag N-substituted carbamoyloxyalkyl-azolium derivatives
MXPA02004145A (es) 1999-11-02 2002-10-17 Basilea Pharmaceutica Ag Derivados de carbamoiloxialquil-azolio n-sustituidos.
DE19961278A1 (de) 1999-12-18 2001-06-21 Cognis Deutschland Gmbh Verwendung von nanoskaligen Antischuppenwirkstoffen
US20030206958A1 (en) 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
NZ521241A (en) 2000-03-07 2004-02-27 Ranbaxy Lab Ltd Azole compounds as therapeutic agents for fungal infections
GB2365770B (en) 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
NZ571597A (en) 2000-12-18 2010-05-28 Cubist Pharm Inc Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides
US6491902B2 (en) 2001-01-29 2002-12-10 Salvona Llc Controlled delivery system for hair care products
US6673373B2 (en) 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
WO2002067880A1 (en) 2001-02-27 2002-09-06 Unilever Plc Treatment of dandruff
US20050209157A1 (en) 2001-03-28 2005-09-22 Owen Donald R Short bioactive peptides and methods for their use
FR2824325B1 (fr) 2001-05-04 2003-08-15 Aventis Pharma Sa Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides
US6797697B2 (en) 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
US20090317502A1 (en) 2001-06-15 2009-12-24 Cuticeuticals, Inc. Dandruff treatment compositions with anti-inflammatory agents including botanic seed oils
WO2003006009A1 (en) 2001-07-11 2003-01-23 Zen-Bio, Inc. Compositions for reducing or preventing cellulite in mammalian skin
IN191819B (ru) 2001-07-19 2004-01-03 Ranbaxy Lab Ltd
EP1482957A4 (en) * 2002-02-15 2006-07-19 Merckle Gmbh ANTIBIOTIC CONJUGATES
US20050131041A1 (en) 2002-04-17 2005-06-16 Mohammad Salman Azole derivatives as antifungal agents
WO2003088932A2 (en) 2002-04-22 2003-10-30 The Procter & Gamble Company Shampoo containing a cationic guar derivative
FR2839448A1 (fr) * 2002-05-07 2003-11-14 Oreal Utilisation d'esters de triclosan, de piroctone et de tropolone dans une composition a liberation controlee
US8367048B2 (en) 2002-06-04 2013-02-05 The Procter & Gamble Company Shampoo containing a gel network
US8361448B2 (en) 2002-06-04 2013-01-29 The Procter & Gamble Company Shampoo containing a gel network
US8349301B2 (en) 2002-06-04 2013-01-08 The Procter & Gamble Company Shampoo containing a gel network
AU2002328176A1 (en) 2002-08-26 2004-03-11 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
JPWO2004028502A1 (ja) 2002-09-27 2006-01-19 持田製薬株式会社 抗真菌剤および抗細菌剤配合洗浄用組成物
TW200407172A (en) 2002-10-17 2004-05-16 Unilever Nv Scalp treatment
US20080200539A1 (en) 2002-11-07 2008-08-21 Bommarito Alexander A Topical antifungal treatment
US7091185B2 (en) 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
US20050142094A1 (en) 2003-03-12 2005-06-30 Manoj Kumar Use of repeat sequence protein polymers in personal care compositions
US20040202636A1 (en) 2003-04-11 2004-10-14 Kaczvinsky Joseph Robert Personal care composition containing an antidandruff component and a nonionic surfactant
CA2522351A1 (en) * 2003-04-18 2004-11-04 Lighthouse Innovations, Llc Compositions and methods for treating body malodor and fungal overgrowth in mammals
EP1643967A1 (en) 2003-06-17 2006-04-12 E.I. Dupont De Nemours And Company Modified soy proteins in personal care compositions
EP1646284A4 (en) 2003-07-18 2008-09-24 Rhode Island Education AZOL DERIVATIVES AND METHOD FOR THEIR PREPARATION
US7250398B2 (en) 2003-09-12 2007-07-31 Novozymes A/S Synthetic antimicrobial polypeptides
US20050282755A1 (en) 2004-03-18 2005-12-22 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
US20050245452A1 (en) 2004-03-29 2005-11-03 Novozymes A/S Pharmaceutical use of novispirins
US20060008538A1 (en) 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
US20060047135A1 (en) 2004-08-30 2006-03-02 Chadwick Scott T Process for preparing chloromethyl di-tert-butylphosphate
WO2006029818A2 (en) 2004-09-16 2006-03-23 Dsm Ip Assets B.V. Cosmetic compositions containing an hydroxamic acid compound optionally in combination with a retinoid
US8916050B2 (en) 2004-09-27 2014-12-23 Special Water Patents B.V. Methods and compositions for treatment of water
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US7812045B2 (en) 2005-03-30 2010-10-12 Daewoong Pharmaceutical Co., Ltd. Antifungal triazole derivatives
EP1867332B1 (en) 2005-04-07 2011-08-24 Toyama Chemical Co., Ltd. Pharmaceutical composition and method using antifungal agent in combination
US7926484B2 (en) 2005-05-03 2011-04-19 Aeon Research And Technology, Inc. Interface accessory for use with an aerosol inhalation system
EP1922067A1 (en) 2005-08-11 2008-05-21 Medical College Of Georgia Research Institute Modified green tea polyphenol formulations
JP4706435B2 (ja) 2005-10-26 2011-06-22 日油株式会社 化粧料、化粧料用ナノ粒子及び化粧料用粉体
EP1951705A4 (en) 2005-10-31 2010-12-15 Dae Woong Pharma NEW ANTIFUNGAL TRIAZOLE DERIVATIVES
US7858581B2 (en) 2005-12-15 2010-12-28 E. I. Du Pont De Nemours And Company PMMA binding peptides and methods of use
WO2007134245A2 (en) 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
DE602007012551D1 (de) 2006-07-07 2011-03-31 Unilever Nv Haarkonditionierungszusammensetzungen gegen schuppen
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
MX2009003680A (es) 2006-10-05 2009-07-17 Univ Johns Hopkins Formulaciones orales, parenterales y topicas dispersables en agua para farmacos deficientemente solubles en agua con el uso de nanoparticulas polimericas inteligentes.
EP1923041A1 (de) 2006-10-20 2008-05-21 Symrise GmbH & Co. KG Verwendung von C10-C14-Alkandiolen zur Herstellung eines Mittels zur Prophylaxe und/oder Behandlung von Malassezia-induzierter Schuppenbildung, sowie Zubereitungen enthaltend C10-C14-Alkandiole
KR100757237B1 (ko) 2006-12-28 2007-09-10 김지활 탈모방지 및 발모촉진 기능을 갖는 나노입자 조성물
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
CA2691274A1 (en) 2007-06-29 2009-01-08 Union Carbide Chemicals & Plastics Technology Llc Hair styling and conditioning personal care films
US8053591B2 (en) * 2007-09-26 2011-11-08 Bezwada Biomedical, Llc Functionalized biodegradable triclosan monomers and oligomers for controlled release
WO2009053163A1 (en) 2007-10-25 2009-04-30 Unilever Plc Hair care composition
MX2010005589A (es) 2007-12-06 2010-06-02 Unilever Nv Composicion para el cuidado personal.
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
WO2009129301A2 (en) 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
CA2722445A1 (en) 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
EP2313083A1 (en) * 2008-07-22 2011-04-27 Lupin Limited Oral compositions of clindamycin
JP5288967B2 (ja) 2008-09-22 2013-09-11 ユー・ディー・シー アイルランド リミテッド 発光素子及びその製造方法、並びに該発光素子を備えるディスプレイ
EP2218447B1 (en) 2008-11-04 2017-04-19 PharmaSol GmbH Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
FR2940281B1 (fr) 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique Ester de diol et d'acide gras polyinsature comme agent anti-acne
US8124577B2 (en) 2009-01-21 2012-02-28 Stepan Company Personal care compositions of sulfonated estolides and other derivatives of fatty acids and uses thereof
CA2760282A1 (en) 2009-05-08 2010-11-11 Unilever Plc Hair treatment composition
CA2763911C (en) 2009-05-29 2018-01-30 Palau Pharma, S.A. Azole antifungal compositions
CN102802593A (zh) 2009-06-24 2012-11-28 荷兰联合利华有限公司 基于凝胶网络的去头屑洗发剂
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
US20110166128A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
WO2007023398A2 (en) * 2005-05-16 2007-03-01 Universite De Geneve Compounds for photochemotherapy
US20070292404A1 (en) * 2006-03-27 2007-12-20 Biosynexus Incorporated Antimicrobial polymer conjugates
WO2008034019A2 (en) * 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
WO2008089185A2 (en) * 2007-01-16 2008-07-24 Enzon Pharmaceuticals, Inc. Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGNIESZKA K. MUSZANSKA; HENK J. BUSSCHER; ANDREAS HERRMANN; HENNY C. VAN DER MEI; WILLEM NORDE;: "Pluroniclysozyme conjugates as anti-adhesive and antibacterial bifunctional polymers for surface coating", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 32, no. 26, 5 May 2011 (2011-05-05), AMSTERDAM, NL, pages 6333 - 6341, XP028097289, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2011.05.016 *
GUIOTTO ANDREA, ET AL: "PEGylation of the antimicrobial peptide nisin A: Problems and perspectives.", IL FARMACO, ELSEVIER FRANCE * EDITIONS SCIENTIFIQUES ET MEDICALES, FR, vol. 58, no. 1, 1 January 2003 (2003-01-01), FR, pages 45 - 50, XP002513890, ISSN: 0014-827X, DOI: 10.1016/S0014-827X(02)01301-0 *
YANG H., LOPINE S.T.;: "Penicillin V-conjugated PEG-PAMAM star polymers.", JOURNAL OF BIOMATERIALS SCIENCE. POLYMER EDITION., VSP, UTRECHT., NL, vol. 14, no. 10, 1 October 2003 (2003-10-01), NL, pages 1043 - 1056, XP008085754, ISSN: 0920-5063, DOI: 10.1163/156856203769231556 *

Also Published As

Publication number Publication date
US20180214472A1 (en) 2018-08-02
NZ619293A (en) 2017-03-31
US20140364595A1 (en) 2014-12-11
AU2012272804B2 (en) 2017-07-06
CN103857440A (zh) 2014-06-11
MX2013015434A (es) 2014-10-14
EP2723452A2 (en) 2014-04-30
CN103857440B (zh) 2018-09-25
EA201490100A1 (ru) 2014-11-28
BR112013033239A2 (pt) 2016-09-06
KR20140057414A (ko) 2014-05-12
US9907812B2 (en) 2018-03-06
JP2018100285A (ja) 2018-06-28
EA032840B1 (ru) 2019-07-31
WO2012177986A3 (en) 2013-03-14
WO2012177986A2 (en) 2012-12-27
JP2014522816A (ja) 2014-09-08
CA2840215A1 (en) 2012-12-27
AU2012272804A1 (en) 2014-01-16
JP6336902B2 (ja) 2018-06-06

Similar Documents

Publication Publication Date Title
EA032840B8 (ru) Пролекарства на основе конъюгатов противогрибковых агентов и их применение
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
WO2012116246A3 (en) Pesticidal compostions and processes related thereto
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
MX361499B (es) Baricitinib deuterado.
IN2015DN01035A (ru)
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MX2015001246A (es) Ibrutinib deuterado.
MX2013004570A (es) Mezclas fungicidas de penflufen.
WO2012047762A3 (en) Antifungal agents
WO2014089177A3 (en) Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
MX2013011548A (es) Formulaciones de agente de curtido particulado sólido.
MX2016002600A (es) Eteraminas a base de glicerina alcoxilada o trimetilolpropano.
PH12015501038A1 (en) Inhibitors of iap
PH12015501400A1 (en) Herbicidal composition comprising a cornexistin
IN2014DN10669A (ru)
MX2014001623A (es) Uso de la cardiotofina-1 para el tratamiento de enfermedades renales.
WO2011124986A3 (en) Polyol modified aminoglycoside-lipid conjugates
WO2014134486A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
GB2523518A (en) Absorbent article with absorbent structure with cross-directionally oriented passageway

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU